Assessment of the adrenergic effects of orphenadrine in rat vas deferens

Journal of Pharmacy and Pharmacology

Volumn 51, Issue 3, 1999, Pages 307-312

  Pubill, D ^a   Canudas, A M ^a   Pallas M ^a   Sureda, F X ^a   Escubedo, E ^a   Camins, A ^a   Camarasa, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; ATROPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NISOXETINE; NORADRENALIN; ORPHENADRINE; PRAZOSIN;

ADRENERGIC ACTIVITY; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ISOTOPE LABELING; MALE; MUSCLE CONTRACTION; MUSCLE TWITCH; NONHUMAN; RAT; VAS DEFERENS;

ADRENERGIC AGENTS; ANIMALS; ATROPINE; BINDING, COMPETITIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRIC STIMULATION; EPIDIDYMIS; FLUOXETINE; LIGANDS; MALE; MUSCARINIC ANTAGONISTS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NOREPINEPHRINE; ORPHENADRINE; PHENCYCLIDINE; PRAZOSIN; RATS; RATS, SPRAGUE-DAWLEY; VAS DEFERENS;

EID: 0032916687     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357991772303     Document Type: Article

References (21)

1. Altamura, A. C., Buccio, M., Colacurcio, F., Colombo, G., Terzi, A. (1986) Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol. Acta Neurol. Napoli 8: 19-26
2. Bassi, S., Albizzati, M. G., Calloni, E., Sbacchi, M., Frattola, L. (1986) Treatment of Parkinson's disease with orphenadrine alone and in combination with L-dopa. Br. J. Clin. Pract. 40: 273-275
3. Bradford, M. M. (1976) A rapid sensitive method for the quantitation of microgram quantitites of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254
4. Contin, M., Riva, R., Albani, F., Baruzzi, A. (1987) Simple and rapid GLC method for the determination of orphenadrine in human plasma. Biomed. Chromatogr. 2: 193-194
5. Danysz, W., Gossel, M., Zajaczkowski, W., Dill, D., Quack, J. (1994) Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. J. Neural. Transm. [PD Sect.] 7: 155-166
6. Danysz, W., Parsons, C. G., Bresink, I., Quack, G. (1995) Glutamate in CNS disorders. A revived target for drug development? Drugs New Perspect. 8: 261-277
7. Finberg, J. P. M., Kremer, I., Spanir, I., Lenox, R. H., Klein, E. (1992) Peripheral noradrenergic function during chronic lithium treatment in the rat. J. Neural Transm. [Gen Sect] 87: 77-83
8. Klockgether, T., Turski, L. (1993) Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia. Ann. Neurol. 34: 585-593
9. Kornhuber, J., Parsons, C. G., Hartman, S., Retz, W., Kalmolz, S., Thome, J., Riederer, P. (1995) Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J. Neural. Transm. [Gen. Sect.] 102: 237-246
10. Lara, H., Bastos-Ramos, W. (1988) Glutamate and kainate effects on the noradrenergic neurons inervating the rat vas deferens. J. Neurosci. Res. 19: 239-244
11. Massamiri, T., Duckles, S. P. (1991) Interactions of sigma and phenylcyclidine receptor ligands with the norepinephrine uptake carrier in the both rat brain and rat tail artery. J. Pharmacol. Exp. Ther. 256: 519-524
12. McPherson, G. A. (1994) RADLIG Version 4.0. A non-linear curve-fitting program for the analysis of radioligand binding experiments. Elsevier-BIOSOFT
13. Midham, R. S. H., Gaind, R., Anstee, B. H., Rimmer, L. (1972) Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced parkinsonism. Physiol. Med. 2: 406-413
14. Olney, J. W. (1986) Excitotoxic amino acids. News Physiol. Sci. 1: 1-19
15. Pubill, D., Canudas, A. M., Gasulla, D., Pallàs, M., Escubedo, E., Camarasa, J. (1996) MK-801 enhances noradrenergic neurotransmission in rat vas deferens. Eur. J. Pharmacol. 303: 171-175
16. 3H]nisoxetine binding in rat vas deferens membranes. Modulation by sigma and PCP ligands. Life Sci. 62: 763-773
17. 3H]-noradrenaline uptake in brain synaptosomes and adrenal chromaffin cells. Br. J. Pharmacol. 103: 1917-1922
18. 3H]desmethylimipramine binding in bovine adrenal medulla: interactions with sigma and (or) phencyclidine-receptor ligands. Can. J. Physiol. Pharmacol. 70: 1508-1514
19. Rudolph, M. I., Arqueros, L., Bustos, G. (1983) L-glutamic acid, a neuromodulator of dopaminergic transmission in the rat corpus striatum. Neurochem. Int. 5: 479-486
20. 14C-tyramine uptake in atria. Eur. J. Pharmacol. 5: 206-298
21. Zee, P., Hespe, W. (1973) Influence of orphenadrine HCl and its N-demethylated derivatives on the in vitro uptake of noradrenaline and 5-hidroxytryptamine by rat brain slices. Neuropharmacology 12: 843-851